Cover Image
市場調查報告書

中東、北非的醫藥品、醫療產業 (季度更新報告)

Middle East And North Africa Pharmaceuticals and Healthcare Report Q2 2017

出版商 BMI Research 商品編碼 361671
出版日期 內容資訊 英文 34 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中東、北非的醫藥品、醫療產業 (季度更新報告) Middle East And North Africa Pharmaceuticals and Healthcare Report Q2 2017
出版日期: 2017年04月26日 內容資訊: 英文 34 Pages
簡介

本報告提供中東、北非 (MENA) 各國的製藥、醫療產業結構和形勢相關分析,最新的市場趨勢 (以季度為基礎) ,及今後的長期性的產業規模的動向估計,產業的課題 (風險) 和未來商機 (利潤) 相關評估,今後的市場成長的機會與課題,域內各國、各地區詳細趨勢,主要企業簡介等資訊彙整,為您概述為以下內容。

BMI產業分析

  • 中東、北非市場最新趨勢 (以季度為基礎)

SWOT分析

  • 中東、北非市場最新趨勢 (以季度為基礎)

產業預測

  • 製藥產業:中東、北非市場最新趨勢 (以季度為基礎)
  • 醫療產業:中東、北非市場最新趨勢 (以季度為基礎)

產業的風險/利潤指標

  • 中東、北非市場最新趨勢 (以季度為基礎)

市場概要

  • 中東、北非市場最新趨勢 (以季度為基礎)

產業的趨勢與發展

  • 中東、北非市場最新趨勢 (以季度為基礎)

地區概要

  • 中東、北非市場最新趨勢 (以季度為基礎)

用語一覽

分析方法

  • 醫藥品支出額的預測模式
  • 醫療費的預測模式
  • 分析方法的相關註記
  • 風險/利潤、等級技術
  • 指標概要
  • 指標的加權

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 2398-1040

BMI View:Opportunities for pharmaceutical companies in the Middle East and North Africa (MENA) region will be diverse. International firms will benefit greatly from identifying the bright spots in the region and avoiding those markets where the risks outweigh the opportunities. Despite the push towards expanding healthcare access throughout the region, longstanding economic and political fragilities, combined with the lasting effects of weak economic growth and low oil prices, will create some tough operating environments for foreign drugmakers. Indeed, the MENA region will remain a challenging, yet commercially attractive, environment for multinational drugmakers.

Headline Expenditure Projections

  • Pharmaceuticals: USD31.8bn in 2016 to USD31.2bn in 2017; a -2.0% y-o-y change in US dollar terms.
  • Healthcare: USD170.8bn in 2016 to USD172.0bn in 2017; a +0.70% y-o-y change in US dollar terms.

Risk/Reward Index

The Middle East & North Africa (MENA) average (47.8) in our Innovative Pharmaceuticals Risk/Reward Index (RRI) slightly underperforms the global average (50.0). The region is highly diverse, with a number of large Gulf States scoring highly for access to, and demand for, innovative medicines. However, a number of significantly underdeveloped markets with low affordability levels, poor access to healthcare services and elevated industry-and-country-specific risks drag the regional score below the global average.

Table of Contents

BMI Industry View

  • Middle East And North Africa - Q2 2017
    • Table: Headline Regional Pharmaceuticals & Healthcare Forecasts (2015-2021)

SWOT

  • Middle East And North Africa - Q2 2017

Industry Forecast

  • Pharmaceutical - Middle East And North Africa - Q2 2017
    • Table: Regional Pharmaceutical Sales, Historical Data And Forecasts (2013-2021)
  • Healthcare - Middle East And North Africa - Q2 2017
    • Table: Regional Pharmaceutical Sales, Historical Data And Forecasts (2013-2021)

Industry Risk Reward Index

  • Middle East & North Africa Risk/Reward Index - Q2 2017

Market Overview

  • Middle East And North Africa - Q2 2017

Regional Overview

  • Middle East & North Africa - Q2 2017

Industry Trends And Developments

  • Regional Round-Up Q2 2017

Glossary

Methodology

  • Pharmaceutical Expenditure Forecast Model
  • Healthcare Expenditure Forecast Model
  • Notes On Methodology
  • Risk/Reward Index Methodology
  • Index Overview
    • Table: Pharmaceutical Risk/Reward Index Indicators
  • Indicator Weightings
Back to Top